Evidence map›Paper›PMID 37732058›Full record

ArticleArchives of medical science : AMS2023

Nanoparticles: a breakthrough in COVID-19 prevention, diagnosis and treatment.

Aleksandra Skwarek, Aleksandra Gąsecka, Miłosz J Jaguszewski, Łukasz Szarpak, Tomasz Dzieciątkowski, Krzysztof J Filipiak

Abstract read
In one paragraph

Article in Archives of medical science : AMS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aleksandra Skwarek1 Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
Aleksandra Gąsecka1 Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
Miłosz J Jaguszewski1 Department of Cardiology, Medical University of Gdansk, Gdansk, Poland.
Łukasz SzarpakMaria Skłodowska-Curie Medical Academy, Warsaw, Poland.
Tomasz DzieciątkowskiDepartment of Medical Microbiology, Medical University of Warsaw, Warsaw, Poland.
Krzysztof J Filipiak1 Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), declared a global pandemic by the World Health Organization (WHO). The three key principles in management of the COVID-19 pandemic are prevention, early detection and targeted treatment. Vaccine-based prevention together with early detection has already proven its efficacy in controlling the pandemic. Early detection of infected patients could substantially accelerate the implementation of treatment, but also help to identify infection hotspots, whereas targeted treatment might destroy the virus and minimize damage to healthy tissue. Nanoparticles hold great promise with respect to these aspects. They may also be the solution to emerging clinical problems such as reinfection, pregnancy-related COVID-19 and coinfection. Here, we aim to discuss the potential applications of nanoparticles to combat the COVID-19 pandemic.

Indexed as

coronavirus disease 2019COVID-19nanoparticlesSARS-CoV-2

Identifiers

PMID37732058
PMCPMC10507787

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.